We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch
Read MoreHide Full Article
ZimVie Inc. (ZIMV - Free Report) recently launched its Biotivity A/C Plus Membrane in the United States. This is a growth factor-rich membrane utilized for site coverage and protection from the oral environment in a range of dental applications.
This latest addition to the company’s portfolio is expected to strengthen ZimVie’s foothold in the expanding dental biomaterials market.
Dental Biomaterials and Barrier Membranes
Dental bone grafting and implant procedures often require the use of protective barrier membranes. These membranes play a crucial role in promoting wound healing, ensuring successful implantation and protecting the surgical site from the hostile oral environment. ZimVie’s Biotivity A/C Plus Membrane is claimed to meet these demands effectively.
It is a barrier membrane that contains an array of growth factors, cytokines, chemokines and hyaluronic acid. These elements are scientifically proven to enhance healing and foster ideal conditions for tissue regeneration and bone formation.
Advantages of Biotivity A/C Plus Membrane Over Conventional A/C Membranes
The Biotivity A/C Plus Membrane has a unique triple-layer structure, which provides enhanced conformability and a higher content of growth factors compared to conventional A/C membranes. This results in improved clinical outcomes.
Image Source: Zacks Investment Research
Further, unlike other A/C membranes, this Biotivity A/C Plus Membrane has not been treated with antibiotics during processing, ensuring a more natural and biocompatible solution. The sterilization process includes the use of the Excellion Process and Electron-Beam irradiation.
Market Prospect
Going by a Mordor Intelligence report, the dental biomaterials market is projected to register a CAGR of 6.8% during the forecast period 2023-2028.
Key growth drivers of the market include the increasing burden of dental disorders, the growth of dental tourism, rising adoption of dental implants and higher disposable income in developing countries. Dental issues such as periodontal disease, tooth decay, oral cancer and dental caries affect billions of people globally, emphasizing the need for dental biomaterials. Additionally, dental tourism, driven by cost savings, may further boost demand for these materials.
Share Price Performance
Over the past year, shares of ZIMV have lost 4.9% compared with an 8.2% decline of the industry.
Cardinal Health stock has risen 35% in the past year. Earnings estimates for the company have increased from $6.65 to $6.66 for 2023 but remained constant at $7.56 for 2024 in the past 30 days.
CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.03%. In the last reported quarter, it posted an earnings surprise of 4.73%.
Estimates for Haemonetics’ 2023 earnings per share have remained constant at $3.82 in the past 30 days. Shares of the company have increased 15.2% in the past year against the industry’s decline of 2.8%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it delivered an earnings surprise of 38.16%.
Estimates for Align Technology’s 2023 earnings have moved up from $8.77 to $8.78 per share in the past 30 days. Shares of the company have increased 37.7% in the past year compared with the industry’s growth of 25%.
ALGN’s earnings beat estimates in three of the trailing four quarters and missed in one. In the last reported quarter, it delivered an earnings surprise of 9.90%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch
ZimVie Inc. (ZIMV - Free Report) recently launched its Biotivity A/C Plus Membrane in the United States. This is a growth factor-rich membrane utilized for site coverage and protection from the oral environment in a range of dental applications.
This latest addition to the company’s portfolio is expected to strengthen ZimVie’s foothold in the expanding dental biomaterials market.
Dental Biomaterials and Barrier Membranes
Dental bone grafting and implant procedures often require the use of protective barrier membranes. These membranes play a crucial role in promoting wound healing, ensuring successful implantation and protecting the surgical site from the hostile oral environment. ZimVie’s Biotivity A/C Plus Membrane is claimed to meet these demands effectively.
It is a barrier membrane that contains an array of growth factors, cytokines, chemokines and hyaluronic acid. These elements are scientifically proven to enhance healing and foster ideal conditions for tissue regeneration and bone formation.
Advantages of Biotivity A/C Plus Membrane Over Conventional A/C Membranes
The Biotivity A/C Plus Membrane has a unique triple-layer structure, which provides enhanced conformability and a higher content of growth factors compared to conventional A/C membranes. This results in improved clinical outcomes.
Image Source: Zacks Investment Research
Further, unlike other A/C membranes, this Biotivity A/C Plus Membrane has not been treated with antibiotics during processing, ensuring a more natural and biocompatible solution. The sterilization process includes the use of the Excellion Process and Electron-Beam irradiation.
Market Prospect
Going by a Mordor Intelligence report, the dental biomaterials market is projected to register a CAGR of 6.8% during the forecast period 2023-2028.
Key growth drivers of the market include the increasing burden of dental disorders, the growth of dental tourism, rising adoption of dental implants and higher disposable income in developing countries. Dental issues such as periodontal disease, tooth decay, oral cancer and dental caries affect billions of people globally, emphasizing the need for dental biomaterials. Additionally, dental tourism, driven by cost savings, may further boost demand for these materials.
Share Price Performance
Over the past year, shares of ZIMV have lost 4.9% compared with an 8.2% decline of the industry.
Zacks Rank and Key Picks
ZimVie currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Cardinal Health (CAH - Free Report) , Haemonetics (HAE - Free Report) and Align Technology (ALGN - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cardinal Health stock has risen 35% in the past year. Earnings estimates for the company have increased from $6.65 to $6.66 for 2023 but remained constant at $7.56 for 2024 in the past 30 days.
CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.03%. In the last reported quarter, it posted an earnings surprise of 4.73%.
Estimates for Haemonetics’ 2023 earnings per share have remained constant at $3.82 in the past 30 days. Shares of the company have increased 15.2% in the past year against the industry’s decline of 2.8%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it delivered an earnings surprise of 38.16%.
Estimates for Align Technology’s 2023 earnings have moved up from $8.77 to $8.78 per share in the past 30 days. Shares of the company have increased 37.7% in the past year compared with the industry’s growth of 25%.
ALGN’s earnings beat estimates in three of the trailing four quarters and missed in one. In the last reported quarter, it delivered an earnings surprise of 9.90%.